Statement of Significance: 32
Molecular motors transduce chemical energy from ATP into the mechanical work inside a cell, 33
powering everything from muscle contraction to vesicular transport. While ATP is the preferred 34 source of energy, there is growing interest in developing alternative sources of energy to gain 35 control over molecular motors. We synthesized a series of synthetic compounds to serve as 36 alternative energy sources for muscle myosin. Myosin was able to use this energy source to 37 generate force and velocity. And by using different isomers of this compound we were able to 38 modulate, and even inhibit, the activity of myosin. This suggests that changing the isomer of the 39 substrate could provide a simple, yet powerful, approach to gain control over molecular motor 40 function. Molecular motors, such as muscle myosin, have evolved to transduce chemical energy 84 from the gamma phosphate bond in adenosine triphosphate (ATP) into mechanical work. This 85 energy is used to power a myriad of intracellular processes, from muscle contraction (1) to the 86 transport of organelles(2), to cytokinesis(3). While ATP is the preferred source of molecular 87 motors, there is growing interest in developing alternative energy sources to control biological 88 motors and thereby control the processes they drive inside the cell(4, 5). For example, the 89 ability to preferentially inhibit the activity of skeletal muscle myosin could aid in the treatment of 90 muscle spasticity that is so prevalent in conditions like cerebral palsy. It would also be 91 advantageous to activate or enhance skeletal muscle myosin function in disorders where neural 92 input to the muscle is compromised, such as multiple sclerosis, ALS, and the "easy muscle 93 fatigue" experienced by individuals with chronic heart failure (CHF). Directly enhancing cardiac 94 myosin function would also be a powerful approach to improve the cardiac contractility in 95 individuals with CHF. In fact, this approach is currently being pursued using 2-deoxy ATP, an 96 analog of ATP (6-8). Thus, gaining control over molecular motors represents a promising area 97 for novel therapeutic approaches to treat many prevalent conditions. Gaining control over 98 molecular motors is also a focus of nanotechnology efforts that aim to build synthetic 99 controllable molecular motor-based nanomachines(9-13). Indeed, biological motors have even 100 been used, in this context, to perform parallel computing tasks(14), where precise control over 101 the motors is critical to proper function of the nanodevice. Thus, there is growing interest in the 102 ability to control molecular motor function both in vivo and in vitro because of the broad and 103 powerful potential that such control would offer to both clinicians and bioengineers. 104
Several different strategies have been employed to gain control over the activation, 105 speed, and directionality of molecular motors. Initial efforts using "caged-ATP", enabled 106 researchers to precisely control the initiation of contraction in muscle, providing novel 107 wavelengths of light in an in vitro motility assay(5). The bulky cis form of AzoTP (which 133 predominates in UV light) likely renders AzoTP unable to bind to myosin's nucleotide binding 134 site, while the flatter trans form (that predominates with visible light exposure), readily binds to 135 the active site much like ATP(5). Thus, this approach creates a type of control that is similar to 136 that of the light-sensitive caged-ATP compounds(21), an "on/off switch", but has the additional 137 advantage of being reversible. However, the control over contraction is less precise than caged-138 ATP because conversion from the cis to trans form of AzoTP is incomplete; indeed even with 139 prolonged exposure to UV 10% of the AzoTP remains in the trans form. This means that myosin 140 function cannot be fully stopped. A further drawback for in vivo applications is that it would be 141 difficult to implement an external light trigger in subcutaneous body tissues such as skeletal and 142 cardiac muscle. Therefore, there is now a need to gain more precise intrinsic control over 143 molecular motors, in which the substrate is modified to alter specific transitions within the 144 molecular motor's mechanochemical cycle (i.e. the cross-bridge cycle in myosin). This would 145 provide a substantially greater degree of control over the motor such that both the activation and 146 the speed of the motor could be precisely modulated rather than simply turning it on and off by 147 affecting binding to the active site. 148
Gaining intrinsic control over molecular motors using alternative substrates requires a 149 detailed mechanistic understanding of how myosin uses these compounds to generate force 150 and motion. For example, despite the fact that substrates can be used by myosin to generate 151 motion, it is not clear how they bind to and interact with myosin's active site. It is also unclear 152 which step or steps in myosin's mechanochemical cycle might be altered to gain control over its 153 function. Achieving this level of knowledge requires a full biophysical characterization of 154 myosin's mechanics and kinetics at both the ensemble and single molecule levels. 155
Herein we report that myosin can use a synthetic azobenzene-based non-nucleoside 156 triphosphate (AzoTP) as an alternative energy source to generate force, as well as velocity, in in 157 vitro assays. We show that myosin's function is profoundly sensitive to the position of the 158 triphosphate moiety (i.e. positional isomers) on the base of the synthetic substrate. In fact, with 159 one isomer myosin was able to generate ~65% of the function elicited when ATP is the energy 160 source, while another isomer reduced myosin's velocity by ~99%; a third isomer inhibited 161 myosin function in the presence of ATP in a dose-dependent manner. We used a series of 162 biophysical experiments, including single molecule laser trap assays, to reveal how myosin 163 used each of these AzoTP isomers to transduce energy, and compared the results with those 164 using ATP. The results demonstrate that subtle structural changes to a synthetic substrate can 165 dramatically alter and thus control myosin's function by affecting the intrinsic properties of its 166 mechanochemical cycle. Thus, positional isomerism provides a powerful new approach to gain 167 control over molecular motor function and may also provide novel mechanistic insights into the 168 fundamental nature, and efficiency, of energy transduction by this prototypical molecular motor. 169
Materials and Methods 170

Chemical synthesis 171
AzoTP compounds ( Fig.1a) were synthesized based on a protocol reported previously(5). 172
Briefly, we added di-tert-butyl N,N-diisopropylphosphoramidite, followed by oxidation with m-173 chloroperoxybenzoic acid to the ortho, meta or para isomers of hydroxy-2-ethoxy azobenzene in 174 dry THF to form the tert-butyl protected monophosphate ester. The ester was deprotected with 175 trifluoroacetic acid and was purified by eluting through a DEAE A-25 anion exchange column. 176
During this process the cation was converted to a triethylammonium salt. A solution of 177 triethylammonium monophosphate salt of the azobenzene was converted to a tributyl 178 ammonium salt by the addition of tributylamine. This monophosphate was coupled with 179 tributylammonium pyrophosphate to obtain tributylammonium salt of azotriphosphate. This was 180 converted to its sodium salt using sodium iodide. The synthetic procedure of each compound is 181 provided in the Supplemental Materials ( Supplementary Fig. S1 ). 182
In vitro functional assays 183
Proteins 184
Myosin and actin used in the all the experiments were purified from chicken pectoralis 185 muscle as previously described(22) with minor modifications as detailed previously(23). Roughly 186 >95% of the myosin in this tissue is composed on the fast type IIb myosin heavy chain 187 isoform(24). The action was isolated as G-actin but then re-polymerized and labeled with 100% 188 TRITC/phalloidin for the in vitro motility assay, and with 50% TRITC/phalloidin and 50% 189 biotin/phalloidin for the laser trap assay experiments. All animal tissue was obtained in 190 accordance with the policies of the National Institute of Health using a protocol approved by the 191
Institutional Animal Care and Use Committee at the University of Massachusetts Amherst. 192
In vitro motility assay 193
The in vitro motility assay was performed as previously described (25) 
Analysis of in vitro motility data 205
The velocity of the actin filaments as well as the percent of filaments moving was 206 determined using an automated filament-tracking ImageJ plugin WRMTRK. Filaments shorter 207 than 0.5 μm were eliminated from the analysis, and filaments with velocities less than 0.13 μm . s -208 1 were considered to be stationary. A typical field of view generated 25-50 filament velocities, 209 and the mean of these velocities was taken as the average velocity for that field of view, with a 210 total of three recordings done for each flow cell. For each condition tested, at least three flow 211 cells were used to generate the data, resulting in at least nine recordings contributing to the 212 overall mean filament velocity for each condition. 213
Single molecule and mini-ensemble laser trap assays 214
The laser trap assays were performed at 25 °C as previously described(26) and the filament was attached to both beads in a three-bead configuration previously detailed(28). 226
Compliance of this bead-actin-bead assembly was minimized by applying 3-4 pN of pretension, 227 and the laser power set such that the combined trap stiffness of the dumbbell was 0.02 pN per 228 nanometer, which was determined based on the Brownian motion of the bead-actin-bead 229 assembly when not attached to myosin using equipartition theory(29). The dumbbell was then 230 brought into contact with the myosin head(s) on the surface by approaching the nitrocellulose 231 coated 3 μm silica bead. 232
Analysis of laser trap assay data 233
To determine the size of myosin's powerstroke (d) and the duration of actomyosin strong 234 binding (ton) the raw actin displacement data were analyzed using a mean-variance analysis as 235 previously described(30). Briefly, the mean and variance of the raw displacement records were 236 calculated within a defined time window (e.g. 30 ms). This window was advanced over the entire 237 displacement record and the calculated mean and variance within each window was plotted in a A separate custom analysis program was used to analyze the mini-ensemble laser trap 250 assay data, to determine peak force and event duration for all recordings. This threshold based 251 program was similar to the method we previously published(31) with minor modifications, 252
including automated detection(26). Briefly, the data was processed with a custom Python script 253 to correct for baseline wander. Analysis of the processed data, including the event detection and 254 measurements, were completed in R © 3.5.2(32) using custom programs with functions from the 255 'tidyverse' and 'gtools' packages(33). Briefly, the baseline corrected data was low-pass filtered 256 using a running mean with a 10 ms (50 data points, at the sampling rate of 5 kHz) window width 257 and the events were identified using two criteria, 1) an +8 nm threshold was set to the running 258 mean to signal the start/end of an event, and 2) the event was included in further analysis if the 259 duration was greater than 10 ms. Event durations were calculated as the time between the 260 start/end (8 nm) thresholds and the time-off measurements were calculated as the time between 261 the end of an event and the start of the subsequent event. Peak forces were calculated by 262 identifying the maximum displacement of each record and converting the displacement in 263 nanometers to forces in pN (0.04 pN . nm -1 ). Plots of the raw data and representative analysis 264 traces were constructed using the 'ggplot2' and 'cowplot' R © -packages(33, 34). The data were 265 then plotted in a histogram ( Fig. 4b ) and the arithmetic means reported ( Fig. 4d-f ). 266 267 268
Molecular modeling and dynamics simulations 269
Atomistic simulations of myosin in complex with ATP or Azo-TP molecules were carried 270 out using CHARMM/OpenMM program(35, 36). The latest CHARMM 36 m force field(37) was 271 applied to model protein, water and ions, and CHARMM general force field (CGenFF)(38) was 272 used to model the small molecules. The initial protein structure was obtained from RCSB 273
Protein Data Bank (PDB) entry 1MMD(39). Coordinates of Mg ++ and water molecules from this 274 PDB structure were also retained. ATP and AzoTP molecules were first generated using 275 CHARMM-GUI(40, 41). The ligand was then translated to the binding pocket of myosin, with the 276 coordinates of TP group replaced by those of adenosine diphosphate•BeF3 in PDB 1MMD and 277 the Azo group reoriented to mimic the binding pose of ADP. The initial structure of myosin-278 ligand complex was energy minimized in vacuum for 5000 steps to remove any steric clashes. It 279 was then placed in a rectangular simulation box containing ~28,000 TIP3P water molecules, 280 such that the minimum distance between protein surface and box edge was at least 12 Å. 9 K + 281 ions were also added to neutralize the system. The simulation box was ~126 * 96 * 78 Å(37), 282 and periodic boundary condition was imposed for all simulations. 283
The solvated systems were energy minimized using steepest descent and adopted basis 284
Newton-Raphson algorithms. Each system was then slowly heated up from 100 K to 300 K in a 285 10-ps simulation, with the heavy atoms of protein and ligand restrained by harmonic potentials 286 with a force constant of 5 kcal/mol/Å(36). Another 1 ns simulation was also performed to 287 equilibrate the system at 300 K and 1 atm, with the retraining potentials slowly reduced to zero. 288
The final production runs were carried out under the same NPT conditions without any restraint, 289 except that the Azo group was restrained at the trans-conformation with a harmonic potential of 290 force constant 5 kcal/mol/Å(36). In all simulations, the nonbonded interactions were truncated at 291 13 Å, and long-range electrostatic interactions were treated with particle mesh Ewald 292 method(42). Lengths of all bonds involving hydrogen atoms were constrained using SHAKE 293 algorithm(43). The time step to integrate the equation of motion was 2 fs, and final production 294 runs lasted for at least 100 ns. 295
Additional statistical analyses 296
Comparisons among the single molecule laser trap assay and motility data were 297 determined using ANOVA and Tukey's post-hoc tests (Sigmaplot 11.0) to locate differences with 298 the alpha level set at p < 0.05. A Student's t-test was used to determine if the ortho-AzoTP 299 resulted in a significant difference in myosin's step size, duration of strongly-bound lifetime (ton) 300 vs ATP. 301
The nonlinear regression for estimating the xDP-release and xTP-binding rates (Fig. 5 ) 302
were performed in R © version 3.5.2 using the nls function from the stats package(32) which 303 optimizes the fit using the least squares method (Gauss-Newton algorithm). Summary statistics 304 from the regression were extracted using the tidy function from the broom package(44). These 305 data were visualized using the ggplot2 package(33). The goodness of fit for regression was 306 determined through the residual plots using the nlsResiduals function in the "nlstools" 307 package(45). 308
Results 309
Positional isomers of AzoTP differentially affect myosin function 310
We synthesized three positional isomers of an azobenzene-based triphosphate (AzoTP) 311
to use as non-nucleoside energy sources for fast skeletal muscle myosin. The phosphate 312 moiety was placed at the ortho, meta or para positions of one of the phenyl rings ( Fig. 1) . Each 313 compound was tested to determine its ability to power muscle myosin as it translocated actin 314 filaments in an in vitro motility assay (Fig. 1b) . The velocity of the actin filaments in the motility 315 assay (Vactin) was determined and compared with the value observed when ATP served as the 316 control substrate (Fig. 1b) . When para-AzoTP was used as the energy source, myosin did not 317 move the actin filaments (Supplemental video 1), suggesting it cannot harness the energy in the 318 triphosphate. Likewise, no filament motion was initially observed when using meta-AzoTP; 319 however upon closer examination over a more extended time scale (2min vs 30sec), there was 320 clear evidence of actin filament motion with meta-AzoTP, albeit with an extremely slow velocity 321 of 70 nm per second, less than 1% of the velocity observed with ATP (Supplemental video 2). 322
Indeed, almost all of the filaments (~90%) moved at a constant velocity of 70 nm/s, suggesting 323 that myosin is still using the energy of meta-AzoTP, but that one or more steps in its 324 mechanochemical cycle was drastically slowed. In contrast to the para and meta isomers, with 325 ortho-AzoTP serving as the energy source, myosin generated a Vactin that was ~65% of that 326 observed using ATP ( Fig. 1a and Supplemental video 3), and as with ATP, >80% of the 327 filaments were motile (Fig. 1c ). These findings demonstrate that myosin can harness the energy 328 from a non-nucleoside triphosphate to power actin filament motion. were mixed with equal amounts of ATP, Vactin was similar to ATP alone, suggesting that they do 352 not affect myosin's interaction with ATP and thus likely do not inhibit myosin function (Fig. 1d) . equal to that of ATP alone (Fig. 1c ), suggesting that the decreased velocity was not due to an 356 increased portion of non-moving filaments. 357
To determine the nature of this inhibition we examined the effect of para-AzoTP on Vactin 358 as a function of the concentration para-AzoTP, initially at a constant ATP concentration of 2mM 359 (Fig. 1d ). This revealed a linear decrease in Vactin as a function of the concentration of para-360
AzoTP. To further delineate the mechanism inhibition we measured the degree of inhibition of 361 three different para-AzoTP concentrations while varying the ATP concentration. These findings 362 indicated that the inhibitory effect of para-AzoTP did not increase as the ATP concentration was 363 decreased ( Supplementary Fig. 2 ), suggesting that para-AzoTP acts as an uncompetitive 364 inhibitor of ATP(46). Importantly, the inhibitory effects were readily reversible, because washing 365 out the para-AzoTP with a 2mM ATP buffer almost completely restored Vactin to the control 366 (ATP) value (Supplemental video 5). 367
The ability of myosin to use ortho-Azo-TP to generate actin filament velocities in the 368 motility assay at 65% of the value with ATP ( Fig. 1b ) enabled us to identify the steps in myosin's 369 mechanochemical cycle that might be altered when by the synthetic substrate. We started this 370 effort by measuring Vactin as a function of the substrate concentration (Fig. 1g ), and found that 371
Vactin was slower with ortho-AzoTP at all substrate concentrations, with the maximum velocity 372 (Vmax) observed to be 65% of that of the value with ATP. Notably at low substrate concentrations 373 (<100uM) the filaments stopped moving with ortho-AzoTP, but filament motion was detected 374 down to 50uM when ATP was the substrate. These data were fit to a Michaelis-Menten 375 relationship, and indicated that the KM for ortho-AzoTP was higher than for ATP, suggesting that 376 ortho-AzoTP has a lower affinity for myosin's nucleotide binding site. However, the decrease in 377
Vactin at saturating substrate concentrations (>1mM) suggested that either myosin's powerstroke 378 is decreased and/or the rate of release of the diphosphate form of the substrate was slower than 379 with ATP(47). 380
Ortho-AzoTP affects myosin's single molecule mechanics and kinetics 381
To more clearly delineate the mechanism underlying the decreased Vactin with ortho-382
AzoTP vs. ATP, we directly measured the size of myosin's powerstroke (i.e. step size) and the 383 duration of actomyosin binding (ton) using a single molecule laser trap assay ( Fig. 2a) . 
404
Compared to ATP, myosin produced a step size (7 nm) that was 20% smaller with ortho-405
AzoTP (Figs. 2b & 2c) , although not significantly different than that observed with ATP (9 nm). 406
More striking, at 10 M, the lifetime of a single actomyosin interaction (ton) was nearly 10-fold longer with ortho-AzoTP vs ATP (Fig. 2c) . Indeed, even when the substrate concentration was 408 increased to 50 µM the binding event lifetimes with ortho-AzoTP remained significantly longer 409 than those at the 10 µM ATP (Fig. 2c ). An equivalent measure of ton at 50 µM ATP could not be 410 obtained because binding events were shorter than the resolution of the instrument (~5-7 ms). 411
The longer ton observed in the single molecule laser trap assay is consistent with the lower KM, 412 from the in vitro motility assay data (Fig. 1g) . Indeed, the single molecule experiments provide 413 much greater spatial and temporal resolution than in the bulk motility assay, where quantifying 414
Vactin at M substrate concentrations can be beyond the resolution of the instrumentation. Thus, 415 these data suggest that ortho-AzoTP either binds much more slowly to myosin in the rigor state 416 or that ortho-AzoTP is much slower to initiate the structural events that cause myosin's 417 dissociation from the actin filament(48). 418
We gained further insight into the mechanism of transduction by combining the step size 419 (d) determined from the single molecule assay (Fig. 2) , with the measurements of Vactin as a 420 function of the substrate concentration in the motility assay ( Fig. 1g) , using a simplified model of 421 myosin's cross-bridge cycle (Fig. 3) . This model estimates the rates of: a) the release of the 422 diphosphate form of azobenzene triphosphate (k-AzoDP) from myosin; and b) the rate of AzoTP 423 binding (k+AzoTP) to myosin's active site(49). The model assumes that ton is composed of the time 424 waiting for the diphosphate form of the substrate to dissociate from myosin (inset Fig. 3) , and 425 the time waiting for the next triphosphate molecule to rebind to myosin and cause dissociation 426 from actin. This was fit to the motility and single molecule data (Fig. 3) where ton is the duration of strong actomyosin binding (obtained by dividing the single molecule 430 step size, d (Fig. 2c) by Vactin at each substrate concentration (Fig. 3) ); k-AzoDP is the rate of 431 438 from 4mM down to 75uM were determined by dividing 439 the average single molecule step size (Fig. 2c) by Vactin at 440 the corresponding substrate concentration (see Fig. 1 ).
441
Event durations for 10uM ATP and 10 and 50uM AzoTP 442 were taken from the values obtained in the single 443 molecule laser trap assay (Fig. 2d) . The data were fit to 
455
The results of modelling indicated that k+AzoTP was ~50% slower for ortho-AzoTP than for ATP 456 (Fig. 3) , consistent with a lower KM from the Michaelis-Menten fit to the Vactin data (Fig. 1g) . In 457 contrast, the model suggested that myosin released AzoDP almost twice as fast as it released 458 ADP (Fig. 3) . These findings suggest that the slower Vactin is due to a slower rate of AzoTP 459 binding to, and dissociating myosin from, the actomyosin rigor complex, combined with a 460 reduced step size. Indeed, the substrate-induced dissociation was so much slower at 10 and 50 461 µM that these data points could not be fit by the model (Fig. 3 ), suggesting that k+AzoTP is likely 462 even slower than our model estimates. Interestingly, the reduction in Vactin comes despite a 463 significant increase in the rate of release of the diphosphate form of the substrate AzoDP, 464 adding further evidence that k+AzoTP is much slower than with ATP. 465
Myosin can harness the energy in ortho-AzoTP to generate force 466
To gain a more complete assessment of myosin's ability to transduce energy from a 467 synthetic energy source we also quantified myosin's force generating capacity with ortho-468
AzoTP. This was done by using the laser trap assay as a picoNewton (pN) force transducer, where force is generated by a mini-ensemble of myosin molecules (Fig. 4a ). Under the control 470 condition with ATP serving as the substrate, the mini-ensemble of myosin molecules (~8) bound 471 to and translocated the actin filament against the spring-like load of the laser trap (Fig. 4b) . The 472 stochastic nature of myosin binding and unbinding to the actin filament causes a distribution of 473 forces to be generated, with peak forces ranging from 0.2 -3.5 pN, and an average force equal 474 to 1pN (Fig. 4c) . Fig. 2a ) except that the concentration of myosin of the surface is increased such that ~8 myosin 480 heads are available to interact with the single actin filament and the substrate concentration was increased to 100uM.
481
Force was determined from the displacement records by multiplying the displacement (d) by the trap stiffness (i.e. 482 Force = ktrap * d). Trap stiffness was typically 0.02 pN . nm -1 as determined by the equipartition method (see Methods). 
492
In the presence of ortho-AzoTP myosin was able to generate roughly 65% of the force 493 observed with ATP (Fig. 4b) . Representative raw records show that the runs of motility of these 494 ensembles were shorter than with ATP ( Fig. 4b) , despite the experiments being performed with 495 events revealed a reduction in the number and amplitude of force generating events (Fig. 4c) , 497 resulting in 35% less peak force than with ATP ( Fig. 4d) . Consistent with the reduction in force, 498 the average lifetime of the binding events was reduced by roughly the same amount as the 499 force (38%, Fig. 4d ). This suggests that the drop in force, relative to ATP, is due to a slowed 500 rate of attachment of myosin heads to the actin filament; the longer time between binding events 501 adds further support for this hypothesis (Fig. 4e ). Despite the reduced force levels, these data 502 do demonstrate that this variant of a non-nucleoside synthetic triphosphate compound can be 503 used by myosin to generate force over a distance, and thus mechanical work, in addition to its 504 ability to propel actin filaments (Fig. 1b) . 505
Similar force measurements could not be made using para-AzoTP because myosin did 506 not generate any movement when it was used as a substrate (Fig. 1b) . Likewise, the extremely 507 slow velocity generated when meta-AzoTP was the substrate (~1% of that with ATP), prohibited 508 the ability to accurately measure the force generating capacity with this substrate. 509
510
Discussion 511
We successfully demonstrated that myosin can transduce chemical energy from a 512 photo-switchable, non-nucleotide triphosphate compound into mechanical work ( Figs. 1 & 4) . 513
Furthermore, by changing only the position of the triphosphate moiety from the ortho to para 514 positions, AzoTP can be transformed from an energy source into an inhibitor of myosin function 515 in the presence of its preferred energy source ATP. In addition, by moving the triphosphate to 516 moiety to the meta position, myosin function can be slowed to <1% of the ATP-driven velocity. 517
Thus, we have demonstrated that myosin's force and motion generating capacity can be 518 intrinsically controlled using a non-nucleoside-based molecule, enabling us to "shift the gears" of 519 this molecular motor. Furthermore, by manipulating the substrate concentration and changing 520 the number of myosin molecules in the assays, we have gained insight into the mechanisms 521 underlying this control over the motor's "transmission". 522
Previous reports of using light-sensitive compounds to power muscle myosin found that 523 specific variants of azobenzene-triphosphate can generate actin filament velocities up to 70% of 524 ATP(5, 50). However, only molecules with the triphosphate moiety in the ortho position were 525 examined, and only under unloaded conditions (e.g. in vitro motility assay or ATPase), in which 526 no external work is performed by the motor. Therefore, our use of the mini-ensemble laser trap 527 assay demonstrates, for the first time, that myosin can harness the energy from AzoTP to 528 produce force against a load and therefore generate mechanical work using a substrate other 529 than its preferred source, ATP (Fig. 4) . This finding provides novel insight into the mechanism of 530 myosin's energy transduction because myosin's force generating capacity is thought to be 531 limited by distinctly different mechanisms than its unloaded velocity(47, 51, 52). In addition, our 532 systematic manipulation of the position of the triphosphate moiety on the azobenzene molecule 533 offers detailed insight into how the substrate might interact with myosin's nucleotide binding site. 534
Ortho-AzoTP slows actomyosin dissociation but accelerates AzoDP release 535
While myosin was able to generate force and velocity using ortho-AzoTP it produced 536 significantly less than the amount it could generate using its preferred source ATP (Figs. 2 and  537   4 ). The ~35% drop in velocity, compared to ATP, could be due to either a decrease in myosin's 538 single molecule step size and/or a slowing of one or more of the kinetic steps that occurs while 539 myosin is bound to actin(47). The results of the single molecule laser trap assay revealed 540 slower kinetics and possibly a reduced step size (Fig. 4) explain the slower velocity. While the 541 effect on steps size was small (7 vs. 9 nm for ortho-AzoTP vs. ATP), the effect on event lifetime 542 was much more striking at 10 µM AzoTP (Figs. 2b and 2d ). Indeed, even at a five-fold higher 543 substrate concentration myosin stayed bound to actin significantly longer than with ATP at 10uM 544 ( Fig. 2d ). This is indicative of a slowed rate of the substrate binding compared to myosin's ATP-545 binding and/or a slower rate of dissociation of myosin from the actin filament ( Figs. 2 and 4) , 546
suggesting that myosin has a weaker affinity for ortho-AzoTP than for ATP, which is consistent 547 with the higher KM observed when measuring Vactin as a function of substrate concentration (Fig.  548 3). 549
In contrast to the slowed rate of substrate binding, our kinetic modeling also suggested 550 that the rate of release of the diphosphate form of ortho-AzoTP (AzoDP) is accelerated 551 compared to the release of ADP (Fig. 3) , which would be consistent with a reduced affinity for 552
AzoDP when myosin is strongly-bound to actin. Thus the 35% reduction in Vactin at saturating 553 substrate concentrations is likely due to a reduction in myosin's step size combined with a 554 slowed rate of AzoTP induced dissociation of actomyosin, and this occurs despite an 555 acceleration of the AzoDP release rate. This is intriguing because this particular kinetic step is 556 thought to limit the contraction velocity in skeletal muscle(53) and thus suggests that ortho-557
AzoTP shifts the step that limits velocity from being substrate release to substrate binding. 558
The decrease in myosin's force-generating capacity was similar in magnitude ( Fig. 4) to 559 the decrease in Vactin (Fig. 1) , at roughly 65% of the value observed with ATP. Force at the 560 molecular level is dependent on the product of the force of a single actomyosin cross-bridge and 561 its duty ratio (i.e. the portion of its cross-bridge cycle spent strongly-bound to the actin filament) 562 (52). Therefore the observed 35% reduction in the peak force-generating capacity (Fig. 4) could 563 be due to a decrease in one or both of these parameters. The decrease in the step size (Fig. 2 ) 564 could be explained by a drop in the force per cross-bridge, however the dramatic decrease in 565 the frequency of binding events, as well as the increase in time between events (Fig. 4f ) 566
suggests that myosin attaches to actin more slowly in the presence of ortho-AzoTP. This is 567 evidenced not only by lower average force, but also by the reduced frequency of binding events 568 and the absence of any high force events (> 1pN, see Fig. 4c ). Myosin's attachment rate is 569 governed by how quickly it can hydrolyze the substrate and how quickly it can go from weakly to 570 strongly interacting with actin(54). Thus, once ortho-AzoTP binds to myosin's active site and 571 Supplementary video 1) suggesting that para-AzoTP binds to actomyosin in the rigor state and prevents the release 574 of the diphosphate form of the compound, or that para-AzoTP is does not bind to the active site. We favor the latter 575 because the mechanism of inhibition appears to be uncompetitive (see Supplementary Fig. 5 ). The transitions 576 marked with a red "X" are unlikely to occur. b) For meta-AzoTP the slowed velocity at saturating substrate 577 concentrations (Fig. 1b) suggest that it was not due to a decrease in the percentage of moving filaments 578 (Supplementary video 2 vs. 8) suggests that the diphosphate form of the substrate is released more slowly than ADP.
579
This idea is depicted as a prolonged xDP lifetime. c) Ortho-AzoTP was used by myosin to generate force and motion 580 but takes a smaller step (d) when binding to actin (Fig. 2c) , has a prolonged rigor lifetime at low ATP (Fig. 2b) , and at 581 least one step off of actin is slowed because it generates ~35% less force than with ATP ( Fig. 4 ). 582 583 causes dissociation from actin, it may have difficulty achieving the proper configuration to break 584 the gamma-phosphate bond in AzoTP(48). This would cause myosin to remain dissociated from 585 actin for a longer period of time than it would with ATP. Therefore, in comparison to myosin's 586 cross-bridge cycle with ATP, these data suggest that at saturating ortho-AzoTP concentrations 587 the most pronounced effect is a slower rate of hydrolysis that greatly increases the time spent 588 off of actin, along with a subtle drop in myosin's step size (Fig.4c ). The steps of the cross-589 bridge cycle thought to be altered based on these findings are represented in the model of the 590 cross-bridge cycle shown in Fig. 5 . Thus, despite being able to use this synthetic energy source to power force and motion, 592 myosin is not able to harness as much of the energy as it can with ATP. This is interesting 593 because nearly all of the contacts between myosin and ATP occur between the gamma 594 phosphate and Mg ++ (55), and should thus interact with the active site in a manner similar to 595 ATP, and possesses nearly the same free energy because it comes from the breakage of the 596 same gamma-phosphate bond. Therefore, the observed altered function suggests that the base 597 portion of ATP must also play a role in proper binding of the substrate to the active site, as well 598
as the efficiency of energy transduction. Indeed, simply rotating the position of the triphosphate 599 moiety on the phenyl ring profoundly impacted myosin function (Fig. 1) . 600
To directly examine the nature of the interactions between the substrate and myosin we 601 performed molecular dynamics simulations in which the substrate was docked in the active site 602 and the nature of the interactions between myosin's ATP-binding site and each substrate were 603 qualitatively determined. In general, these simulations show that the ortho version of AzoTP 604 maintains a binding pose in the active site that is quite similar to ATP (Supplemental movie 6), 605 providing potential insight into why it is a much better substrate for myosin than either the para 606 or meta versions of AzoTP. Thus the 35% decrease in force and velocity observed with ortho-607
AzoTP may be due to the subtle variations in its interactions with myosin. 608
Para-AzoTP is an uncompetitive inhibitor of ATP 609
In contrast to the relatively high efficiency of energy transduction observed using the 610 ortho form of AzoTP, myosin did not move in presence of the para isomer of AzoTP (Fig. 1) . 611
Interestingly, when mixed with ATP in the motility assay the para variant of AzoTP inhibited 612 myosin function in a dose-dependent manner (Fig. 1d ), reducing velocity by 50% when both 613 substrates were set to an equal concentration of 2mM. The inhibition was readily reversible 614 (Supplemental video 5), however it was less pronounced at lower ATP concentrations 615 (Supplemental Fig. 2) as would be expected with a competitive inhibition mechanism(56). 616
Indeed, the data are most consistent with an uncompetitive or anti-competitive mechanism(56). 617
This form of inhibition putatively operates through a mechanism in which the inhibitor recognizes 618 and traps the enzyme substrate complex, creating a branch in the canonical pathway(57). There 619 are previous reports of uncompetitive inhibitors of myosin, however they typically act to prevent 620 actomyosin binding, and as a consequence, actin-induced acceleration of Pi release from the 621 active site, trapping myosin in an unbound or weakly bound state(58). With para-AzoTP the 622 actin filaments still move at a very slow velocity at saturating para-AzoTP concentrations, 623
suggesting that it inhibits product release on actin (e.g. ADP-release) and/or slows ATP-induced 624 dissociation from actin. This is an important finding because the ability to inhibit myosin is a very 625 powerful tool in biology(58), thus this provides researchers with a new inhibitor that affords the 626 ability to more precisely characterize the mechanisms of cellular processes driven by myosin. 627
The reversibility of the compound also presents an advantage over other compounds such as 628 blebbistatin which are typically non-reversible(59). 629
Our molecular dynamics simulations with this compound were initiated with para-AzoTP 630 in the active site, which may be a rare event in the in vitro motility assay, but nonetheless show 631 that the triphosphate moiety can fit into myosin's ATP-binding site. However, the simulations 632 also indicate that this phenyl ring makes strong contact with a tyrosine residue near the ATP-633 binding site and can lead to significant deformation of the loop (Supplemental movie 6). Thus, it 634 is somewhat surprising that despite being a triphosphate compound it does not appear to 635 competitively inhibit myosin. One possible mechanism of action to explain this discrepancy is 636 that para-AzoTP recognizes when myosin has a nucleotide in the active site (ADP or ATP) and 637 traps myosin in actin bound state, as uncompetitive inhibitor (see Fig. 5 ). 638
Meta-AzoTP greatly slows myosin's velocity 639
Myosin's mechanochemical cycle seems to be altered in a distinctly different way when 640 meta-AzoTP is the substrate. Myosin moves actin but at only ~1% of the velocity of ATP, 641 despite all the filaments moving in a continuous pattern (see Supplemental video 2), seemingly 642 shifting it into a "low gear". Velocity, in the motility assay, is believed to be limited by the rate at 643 which myosin detaches from actin(51). This detachment rate is governed by how quickly myosin 644 can release the diphosphate form of the substrate and then rebind a new triphosphate 645 substrate. Therefore one, or both, of these parameters may be slowed with meta-AzoTP. 646
However, the observation that the motion was continuous, combined with the observation that 647 the Vactin is not increased by doubling the substrate concentration to 4mM (see Supplementary  648 video 7 compared to Supplemental video 2) suggests that the slowed Vactin is not due to a 649 prolonged rigor state. Rather, since velocity is thought to be limited by the rate of release of the 650 diphosphate form of the substrate at saturating substrate concentrations(53) this suggests that 651 myosin is trapped in a state waiting for the active site to release the meta-AzoDP (Fig. 5 ). Thus 652 myosin might have a very high affinity for the meta form of AzoDP, which would imply that this 653 fast skeletal muscle myosin could be manipulated to take on the properties of a much slower 654 myosin, such as smooth muscle myosin(47), by simply changing the isomer of the substrate. 655
Since the structural change to the substrate is relatively minor yet the effect on myosin is 656 pronounced, control of the motor in this way could afford researchers with a powerful tool to 657 gain precise detail of the mechanisms that govern, and gate, substrate binding and release from 658 the active site. More broadly, it could be used to provide new insights into how myosin 659 transduces chemical energy from the breakage of the gamma bond of a triphosphate-based 660 compound into force and motion. 661
Conclusion 662
Myosin, and evolutionarily-related ATPases, have evolved over billions of years to bind 663 to, and harness the energy of, ATP hydrolysis to perform various intracellular tasks(60). Thus, it 664
is not surprising that it has been quite challenging to develop an alternative form of energy that 665 myosin can harness to transduce chemical energy into mechanical work as efficiently as 666
